Convincing FDA Medical Reviewers to Lift a Clinical Hold on Gene Therapy Trials
When the FDA places a clinical trial on hold following a Serious Adverse Event (SAE), getting the trial resumed requires presenting immutable vector biodistribution toxicology.
Vishal VermaCTO & Co-Founder, Dehurdle
March 22, 20234 min read
The Clinical Hold Resolution Presentation
Recommended Spoken Script
"Our preclinical toxicology reassessment proves the immune response was triggered by viral capsid antibody cross-reactivity at the highest dose tier. We have amended our investigational protocol to include mandatory baseline antibody screening and a 50% dose reduction, establishing a proven safety margin for trial resumption."
The 2-Minute Practice Drill
2-Minute Spoken Drill
The 2-Minute Practice Drill
Practice FDA clinical hold discussions in Dehurdle.
Follow Dehurdle on Google
Add Dehurdle to your Google Preferred Sources to see our playbooks in your AI Overviews and Google Search.